Work

Evaluating Suspected Tumor Recurrence with Epidermal Growth Factor Receptor–Targeted [ 89 Zr]Zr-Panitumumab PET/CT

Year: 2026

Type: article

Abstract: Panitumumab is a therapeutic, fully human monoclonal antibody that targets antiepidermal growth factor receptor, which is overexpressed in head and neck squamous cell carcinoma ([1][1]). [89Zr]Zr-panitumumab is manufactured by chelation of the antibody to 89Zr and is being assessed as a tumor-

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.125.271333